Literature DB >> 32804243

PDCD4 limits prooncogenic neuregulin-ErbB signaling.

Juan Carlos Montero1, Atanasio Pandiella2.   

Abstract

The neuregulins and their ErbB/HER receptors play essential roles in mammalian development and tissue homeostasis. In addition, deregulation of their function has been linked to the pathogenesis of diseases such as cancer or schizophrenia. These circumstances have stimulated research into the biology of this ligand-receptor system. Here we show the identification of programmed cell death protein-4 (PDCD4) as a novel neuregulin-ErbB signaling mediator. Phosphoproteomic analyses identified PDCD4 as protein whose phosphorylation increased in cells treated with neuregulin. Mutagenesis experiments defined serine 67 of PDCD4 as a site whose phosphorylation increased upon activation of neuregulin receptors. Phosphorylation of that site promoted degradation of PDCD4 by the proteasome, which depended on exit of PDCD4 from the nucleus to the cytosol. Mechanistic studies defined mTORC1 and ERK1/2 as routes implicated in neuregulin-induced serine 67 phosphorylation and PDCD4 degradation. Functionally, PDCD4 regulated several important biological functions of neuregulin, such as proliferation, migration, or invasion.

Entities:  

Keywords:  Breast cancer; ErbB receptors; Neuregulin; PDCD4

Year:  2020        PMID: 32804243     DOI: 10.1007/s00018-020-03617-5

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  52 in total

1.  Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme.

Authors:  J C Montero; L Yuste; E Díaz-Rodríguez; A Esparís-Ogando; A Pandiella
Journal:  Mol Cell Neurosci       Date:  2000-11       Impact factor: 4.314

2.  The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function.

Authors:  Juan C Montero; Ruth Rodríguez-Barrueco; Laura Yuste; Pedro P Juanes; Joana Borges; Azucena Esparís-Ogando; Atanasio Pandiella
Journal:  Mol Biol Cell       Date:  2006-11-15       Impact factor: 4.138

Review 3.  ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

Authors:  Carlos L Arteaga; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

Review 4.  Membrane-anchored growth factors.

Authors:  J Massagué; A Pandiella
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

5.  Multiple essential functions of neuregulin in development.

Authors:  D Meyer; C Birchmeier
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

Review 6.  ErbB receptors and signaling pathways in cancer.

Authors:  Nancy E Hynes; Gwen MacDonald
Journal:  Curr Opin Cell Biol       Date:  2009-02-07       Impact factor: 8.382

Review 7.  Neuregulins and cancer.

Authors:  Juan Carlos Montero; Ruth Rodríguez-Barrueco; Alberto Ocaña; Elena Díaz-Rodríguez; Azucena Esparís-Ogando; Atanasio Pandiella
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

Review 8.  Targeting the EGF/HER Ligand-Receptor System in Cancer.

Authors:  Azucena Esparís-Ogando; Juan Carlos Montero; Joaquín Arribas; Alberto Ocaña; Atanasio Pandiella
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

9.  The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system.

Authors:  S Britsch; L Li; S Kirchhoff; F Theuring; V Brinkmann; C Birchmeier; D Riethmacher
Journal:  Genes Dev       Date:  1998-06-15       Impact factor: 11.361

10.  Isoform-specific expression and function of neuregulin.

Authors:  D Meyer; T Yamaai; A Garratt; E Riethmacher-Sonnenberg; D Kane; L E Theill; C Birchmeier
Journal:  Development       Date:  1997-09       Impact factor: 6.868

View more
  3 in total

Review 1.  Dissecting the Roles of PDCD4 in Breast Cancer.

Authors:  Qian Cai; Hsin-Sheng Yang; Yi-Chen Li; Jiang Zhu
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

2.  LncRNA NR2F2-AS1 functions as a tumor suppressor in gastric cancer through targeting miR-320b/PDCD4 pathway.

Authors:  Ming Luo; Shuangya Deng; Tong Han; Yanglu Ou; Yongjun Hu
Journal:  Histol Histopathol       Date:  2022-01-20       Impact factor: 2.130

3.  Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer.

Authors:  Juan Carlos Montero; Elisa Calvo-Jiménez; Sofía Del Carmen; Mar Abad; Alberto Ocaña; Atanasio Pandiella
Journal:  J Exp Clin Cancer Res       Date:  2022-03-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.